Home > Insider Trading > Filing (0001725160-23-000031)

Filing Details

Accession Number:: 0001725160-23-000031
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2023-02-14 19:07:56
Reporting Period:: 2023-02-13

Accepted Time:: 2023-02-14 19:07:56
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1725160	Zentalis Pharmaceuticals Inc.	ZNTL	Pharmaceutical Preparations (2834)	823607803

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1807484	D. Kevin Bunker	C/O Zentalis Pharmaceuticals, Inc. 1359 Broadway Suite 1710 New York NY 10018	Chief Scientific Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2023-02-13	3,807	$20.42	871,657	No	4	S	Direct
Common Stock	Disposition	2023-02-14	6,500	$19.98	865,157	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct
No	4	S	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	350	Indirect	As UTMA custodian for sons
Common Stock	95,000	Indirect	See Footnote

Footnotes

The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units.
The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $19.79 to $20.64. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The sale reported in this Form 4 was effected pursuant to a plan that complies with Rule 10b5-1 and expires July 31, 2023.
The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $19.73 to $20.29. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Represents shares nominally held by Sundog Ranch, Inc. on behalf of the Bunker Family Protection Trust, the sole shareholder of Sundog Ranch, Inc. The Reporting Person and his wife are the primary beneficiaries of the Bunker Family Protection Trust and the Reporting Person and his wife are also directors of Sundog Ranch, Inc. The Reporting Person disclaims beneficial ownership of the securities held by Sundog Ranch, Inc. except to the extent of his pecuniary interest therein, if any.